Key points are not available for this paper at this time.
This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy. The survival rates compare favorably with the recently published results of clinical trials worldwide.
Cooper et al. (Fri,) studied this question.